# Soligenix, Inc.: overview SNGX · Nasdaq · CIK 812796 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sngx.md) · [Financials](/companies/sngx/financials.md) · [Filings](/companies/sngx/filings.md) · [Insiders](/companies/sngx/insiders.md) Latest reported revenue: [$0](/filings/0001104659-26-037701.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Mar 31, 2026 (XBRL us-gaap:Revenues, accession 0001104659-26-037701). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0 d](/filings/0001104659-25-108475.md) | [0.0 d](/filings/0001104659-26-037701.md) | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.78)](/filings/0001104659-25-108475.md) | not reported | [(0.97)](/filings/0001104659-26-057904.md) | [(0.82)](/filings/0001104659-26-092681.md) | [(0.58)](/filings/0001104659-25-108475.md) | not reported | [(0.28)](/filings/0001104659-26-057904.md) | [(0.12)](/filings/0001104659-26-092681.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | [(2,933) d](/filings/0001104659-25-108475.md) | [(2,747) d](/filings/0001104659-26-037701.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.8](/filings/0001558370-23-005304.md) | [0.9](/filings/0001558370-24-003402.md) | [0.8](/filings/0001558370-25-003459.md) | [0.1](/filings/0001104659-26-037701.md) | not reported | | Gross margin | % | [11.6%](/filings/0001558370-23-005304.md) | [42.0%](/filings/0001558370-24-003402.md) | [11.6%](/filings/0001558370-25-003459.md) | not reported | not reported | | Operating margin | % | [(1589.2%)](/filings/0001558370-23-005304.md) | [(1500.6%)](/filings/0001558370-24-003402.md) | [(917.1%)](/filings/0001558370-25-003459.md) | [(7907.7%)](/filings/0001104659-26-037701.md) | not reported | | Net margin | % | [(1522.7%)](/filings/0001558370-23-005304.md) | [(1454.1%)](/filings/0001558370-24-003402.md) | [(731.6%)](/filings/0001558370-25-003459.md) | [(6925.1%)](/filings/0001104659-26-037701.md) | not reported | | Diluted EPS | $ per share | [(4.69)](/filings/0001558370-23-005304.md) | [(4.81)](/filings/0001558370-24-003402.md) | [(12.66)](/filings/0001558370-25-003459.md) | [(4.98)](/filings/0001104659-26-037701.md) | [(2.14)](/filings/0001104659-26-037701.md) | | Free cash flow | $m | not reported | not reported | not reported | not reported | [(10.3)](/filings/0001104659-26-037701.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sngx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $83.0k | 209,507 | | New +209,507 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $82.2k | 207,492 | | New +207,492 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $62.2k | 157,119 | | Added +136,320 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $47.6k | 120,267 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $32.1k | 81,005 | | Added +22,605 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $21.4k | 53,914 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $15.1k | 38,046 | | New +38,046 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.4k | 3,592 | | Unchanged | | [JONES FINANCIAL COMPANIES LLLP](/funds/815917.md) | 2026-06-30 | $507 | 1,236 | | Added +1,136 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $98 | 245 | | Reduced −60 | ## Recent filings [All 987 filings](/companies/sngx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-21 | 20:30 ET | [8-K](/filings/0001104659-26-109329.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-109329 | | 2026-08-07 | 20:05 ET | [10-Q](/filings/0001104659-26-092681.md) | Quarterly report, period 2026-06-30 | 0001104659-26-092681 | | 2026-08-03 | 20:05 ET | [DEF 14A](/filings/0001104659-26-089789.md) | Proxy statement, period 2026-09-17 | 0001104659-26-089789 | | 2026-06-26 | 20:06 ET | [8-K](/filings/0001104659-26-078251.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-078251 | | 2026-06-12 | 20:05 ET | [8-K](/filings/0001104659-26-073430.md) | 3.01 Delisting notice; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-073430 | | 2026-05-28 | 21:21 ET | [8-K](/filings/0001104659-26-067649.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-067649 | | 2026-05-08 | 20:05 ET | [10-Q](/filings/0001104659-26-057904.md) | Quarterly report, period 2026-03-31 | 0001104659-26-057904 | | 2026-04-28 | 11:30 ET | [8-K](/filings/0001104659-26-049787.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-049787 | | 2026-03-31 | 20:05 ET | [10-K](/filings/0001104659-26-037701.md) | Annual report, period 2025-12-31 | 0001104659-26-037701 | | 2026-02-12 | 21:05 ET | [8-K](/filings/0001104659-26-014267.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-014267 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-037701.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 812796 - Tickers: SNGX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.